Peptide vaccines in cancer-old concept revisited.
Peptide vaccines in cancer-old concept revisited.
复制标题
DOI：
10.1016/j.coi.2016.11.001
复制
发表时间：
2017-04
影响因子：
7
通讯作者：
Celis E
中科院分区：
文献类型：
--
作者：
Kumai T;Kobayashi H;Harabuchi Y;Celis E
合成肽疫苗旨在引发和扩增能够控制或根除肿瘤的肿瘤特异性T细胞。尽管基于临床前研究的期望很高，但使用肽疫苗的临床试验结果令人失望。因此，该领域的许多研究人员认为肽疫苗已经过时，不再适用于癌症治疗。然而，最近在理解免疫佐剂的关键作用、疫苗施用模式和T细胞动力学方面的进展导致了这种方法的重生，并重新考虑使用肽疫苗治疗恶性疾病。
Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.